CLASS ACTION UPDATE for NNOX, GLNG and BMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

CLASS ACTION UPDATE for NNOX, GLNG and BMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

The MarketWatch News Department was not involved in the creation of this content.

September 29, 2020 (ACCESSWIRE via COMTEX) —
NEW YORK, NY / ACCESSWIRE / September 29, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

NNOX Shareholders Click Here: https://www.zlk.com/pslra-1/nano-x-imaging-ltd-information-request-form?prid=9673&wire=1GLNG Shareholders Click Here: https://www.zlk.com/pslra-1/golar-lng-limited-loss-submission-form?prid=9673&wire=1BMRN Shareholders Click Here: https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form?prid=9673&wire=1

* ADDITIONAL INFORMATION BELOW *

Nano-X Imaging Ltd. (NASDAQ:NNOX)

NNOX Lawsuit on behalf of: investors who purchased August 21, 2020 – September 15, 2020Lead Plaintiff Deadline : November 16, 2020TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/nano-x-imaging-ltd-information-request-form?prid=9673&wire=1

According to the filed complaint, during the class period, Nano-X Imaging Ltd. made materially false and/or misleading statements and/or failed to disclose that: (1) Nano-X’s commercial agreements and its customers were fabricated; (2) Nano-X’s statements regarding its “novel” Nanox System were misleading as the Company never provided data comparing its images with images from competitors’ machines; (3) Nano-X’s submission to the U.S. Food and Drug Administration admitted the Nanox System was not original; and (4) as a result, Defendants’ public statements were materially false and/or misleading at all relevant times.

Golar LNG Limited (NASDAQ:GLNG)

GLNG Lawsuit on behalf of: investors who purchased April 30, 2020 – September 24, 2020Lead Plaintiff Deadline : November 23, 2020TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/golar-lng-limited-loss-submission-form?prid=9673&wire=1

According to the filed complaint, during the class period, Golar LNG Limited made materially false and/or misleading statements and/or failed to disclose that: (1) certain employees, including the Chief Executive Officer of Hygo Energy Transition Ltd. f/k/a Golar Power Limited (“Hygo”), had bribed third parties, thereby violating anti-bribery policies; (2) as a result, the Company was likely to face regulatory scrutiny and possible penalties; (3) as a result of the foregoing reputational harm, Hygo’s valuation ahead of its initial public offering would be significantly impaired; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

BMRN Lawsuit on behalf of: investors who purchased February 28, 2020 – August 18, 2020Lead Plaintiff Deadline : November 24, 2020TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form?prid=9673&wire=1

According to the filed complaint, during the class period, BioMarin Pharmaceutical Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec’s durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.55 Broadway, 10th FloorNew York, NY [email protected]: (212) 363-7500Fax: (212) 363-7171www.zlk.com

SOURCE: Levi & Korsinsky, LLP

View source version on accesswire.com: https://www.accesswire.com/608386/CLASS-ACTION-UPDATE-for-NNOX-GLNG-and-BMRN-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

COMTEX_372070132/2457/2020-09-29T17:25:13

Is there a problem with this press release? Contact the source provider Comtex at [email protected] You can also contact MarketWatch Customer Service via our Customer Center.

Copyright 2020 ACCESSWIRE

The MarketWatch News Department was not involved in the creation of this content.

Source Article